

Attorney Docket No.: RTS-0333
Inventors: Bennett and Dobie
Serial No.: 10/008,789
Filing Date: November 8, 2001
Page 2

Listing of Claims:

Sub C1

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to a 5'-untranslated region, a start codon region, a coding region, or a 3'-untranslated region of a nucleic acid molecule of SEQ ID NO: 3 encoding thyroid hormone receptor interactor 6 (~~SEQ ID NO: 3~~) wherein said compound specifically hybridizes with ~~nucleic acid molecule encoding thyroid hormone receptor interactor 6~~ one of said regions and inhibits the expression of thyroid hormone receptor interactor 6.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled)

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Attorney Docket No.: RTS-0333
Inventors: Bennett and Dobie
Serial No.: 10/008,789
Filing Date: November 8, 2001
Page 3

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 ~~(canceled)~~

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Attorney Docket No.: RTS-0333
Inventors: Bennett and Dobie
Serial No.: 10/008,789
Filing Date: November 8, 2001
Page 4

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

*2
B
3
5
C*
Claim 15 (currently amended): A method of inhibiting the expression of thyroid hormone receptor interactor 6 in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of thyroid hormone receptor interactor 6 is inhibited.

Claim 16-18 (canceled)

Claim 19 (original): The compound of claim 1 targeted to a nucleic acid molecule encoding thyroid hormone receptor interactor 6, wherein said compound specifically hybridizes with and differentially inhibits the expression of one or more of the variants of thyroid hormone receptor interactor 6 relative to the remaining variants of thyroid hormone receptor interactor 6.

Claim 20 (original): The compound of claim 19 targeted to a nucleic acid molecule encoding thyroid hormone receptor interactor 6, wherein said compound hybridizes with and specifically inhibits the expression of TRIP6-I.